GlassScriptPhysician profile
Douglas B Moore
NPI 1396064804
$8,043.09
in general payments reported to CMS, 2019-2025
54 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $673 · 2021: $1,156 · 2022: $1,235 · 2023: $1,375 · 2024: $1,350 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,211.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $776.84 | 2021-2025 | |
| Amgen INC. | $681.44 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $513.05 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $469.00 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lundbeck LLC | $456.10 | 2022-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $416.01 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.85 | 2020-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $344.10 | 2022-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $292.83 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $289.76 | 2021-2025 | Hyqvia, Trintellix |
| Glaxosmithkline, LLC. | $263.76 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Daiichi Sankyo INC. | $250.13 | 2019-2025 | Injectafer |
| Abbott Laboratories | $234.99 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Lilly USA, LLC | $221.29 | 2021-2025 | Jardiance, Mounjaro |
| Insulet Corporation | $204.25 | 2019-2023 | Omnipod |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.